Following the ruling of the European Court of Justice on the Kanavape case in November 2020, which established that CBD, extracted from the entire hemp plant (including leaves and flowers), should not be classified as a drug, the European Industrial Hemp Association (EIHA) kindly asked DG Grow to update the Cosmetic ingredient database (CosIng)1 accordingly. More specifically, EIHA requested to lift all bans on Cannabis Sativa L. (restricted under ref. II/306: narcotic) and to integrate new INCI entries.